Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

2012

Parker, 2013, Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial, BJU Int, 111, 697, 10.1111/bju.12087

Fisher, 2015, Two-stage individual participant data meta-analysis and generalized forest plots, Stata Journal, 15, 369, 10.1177/1536867X1501500203

2017

Tierney, 2017, Timely and reliable evaluation of the effects of interventions: a framework for adaptive meta-analysis (FAME), Trials, 18, P351

Vale, 2016, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol, 17, 243, 10.1016/S1470-2045(15)00489-1

Rydzewska, 2017, Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis, Eur J Cancer, 84, 88, 10.1016/j.ejca.2017.07.003

Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

Fizazi, 2017, Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174

Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928

Parker, 2018, Radiotherapy to the primary tumour for newly-diagnosed, metastatic prostate cancer: a randomised controlled phase III trial (STAMPEDE), Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3

Boeve, 2019, Eur Urol, 75, 410, 10.1016/j.eururo.2018.09.008

James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900

Yusuf, 1985, Beta blockade during and after myocardial infarction: an overview of the randomized trials, Prog Cardiovasc Dis, 27, 335, 10.1016/S0033-0620(85)80003-7

Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186

Fisher, 2011, A critical review of methods for the assessment of patient-level interactions in individual patient data (IPD) meta-analysis of randomised trials, and guidance for practitioners, J Clin Epidemiol, 64, 949, 10.1016/j.jclinepi.2010.11.016

Fisher, 2017, Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?, BMJ, 356, j573, 10.1136/bmj.j573

Vale, 2018, What is the optimal systemic treatment for men with metastatic, hormone- naive prostate cancer? A STOPCAP systematic review and network meta-analysis, Ann Oncol, 29, 1249, 10.1093/annonc/mdy071

Blanchard, 2017, A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: a GETUG-AFU trial, Cancer Radiother, 21, 491, 10.1016/j.canrad.2017.06.007

Boeve, 2018, A prospective, randomised controlled trial in patients with primary bone metastatic prostate cancer (MPCA) receiving either androgen deprivation therapy (ADT) or ADT combined with concurrent radiation therapy to the prostate, J Urol, 199, e231

Freeman, 2018, A framework for identifying treatment-covariate interactions in individual participant data network meta-analysis, Res Synth Methods, 9, 393, 10.1002/jrsm.1300

Gillessen, 2018, Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, Eur Urol, 73, 178, 10.1016/j.eururo.2017.06.002